Dasatinib + Quercetin

D+Q is the most scientifically grounded senolytic intervention in existence. It is also the only compound in this reference that genuinely requires a physician to use safely. Those two facts coexist without contradiction.

The central tension resolved: Dasatinib + Quercetin is not a community invention based on speculative biology. It was developed by Mayo Clinic researchers, backed by rigorous preclinical evidence, moved into humans through a systematic clinical trial program, and has produced the first direct tissue evidence that a pharmacological intervention reduces senescent cell burden in living humans. This is landmark science. The Geroscience Hypothesis — that clearing senescent cells improves human healthspan — has received its first human confirmation from this research program. No other senolytic combination has this evidence base. The community is correct to take D+Q seriously.

The problem is the gap between the clinical trial context and community self-administration. In the clinical trials: patients were selected by cardiologically appropriate QT intervals; CBC confirmed no baseline cytopenias; medication lists were reviewed for CYP3A4 interactions; physicians were available when the one SAE occurred. In community use: typically none of these safeguards exist. Dasatinib is a prescription oncology drug with FDA-labeled warnings for pleural effusion, QT prolongation, myelosuppression, and pulmonary arterial hypertension. The intermittent senolytic protocol has substantially less risk than chronic CML dosing. But 'substantially less than chemotherapy' and 'safe without monitoring' are not the same statement.

The healthy aging application — the community's primary motivation — is the most biologically compelling and least clinically validated aspect of D+Q use. The mechanism supports it perfectly: healthy middle-aged adults do accumulate senescent cells with age; clearing them should reduce chronic SASP-driven inflammation; the cascade of benefits documented in disease populations should apply, likely in attenuated form, in lower-burden healthy populations. Whether it does — and how much — requires clinical trials in healthy adults that do not yet exist.